2024
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomeNet Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty
Yaesoubi R, Kunst N. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty. Medical Decision Making 2024, 44: 770-786. PMID: 39056310, PMCID: PMC12181631, DOI: 10.1177/0272989x241262343.Peer-Reviewed Original ResearchResults of cost-effectiveness analysesNet monetary benefitCost-effectiveness planeCost-effectiveness analysisMonetary benefitsDecision uncertaintyDecision problemEffect estimatesHypothetical decision problemResults of economic evaluationsValue-of-informationDecision makersCost-effectiveness ratioEconomic evaluation studiesCorrelated costsHigh varianceLevel of uncertaintyParameter uncertaintiesEconomic evaluationMagnitude of parametersMakersDecisionUncertaintyCostMonetaryCost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.Peer-Reviewed Original ResearchIncremental net monetary benefitHereditary hemorrhagic telangiectasiaStandard-of-careBevacizumab therapyWillingness-to-payNet monetary benefitHemorrhagic telangiectasiaWillingness-to-pay thresholdsStandard-of-care strategiesCare of patientsCost-effectiveness analysisAnti-VEGF bevacizumabSystemic antiangiogenic therapyCurrent standard-of-careMonetary benefitsTime horizonFormulary placementHealthcare resource utilizationStandard of careLifetime time horizonPatient quality-of-lifeScenario analysisProbabilistic sensitivity analysesIV bevacizumabAnti-VEGFCost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Tormey C, Krumholz H, Cuker A, Goshua G. Cost-effectiveness of rapid vs in-house vs send-out ADAMTS13 testing for immune thrombotic thrombocytopenic purpura. Blood Advances 2024, 8: 2279-2289. PMID: 38502197, PMCID: PMC11116991, DOI: 10.1182/bloodadvances.2024012608.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraPLASMIC scoreThrombotic thrombocytopenic purpuraThrombocytopenic purpuraADAMTS13 testingIncremental net monetary benefitPer-patient cost savingsTherapeutic plasma exchangeBase-case analysisMarkov cohort simulationProbabilistic sensitivity analysesAmount of QALYEmpirical therapyADAMTS13 assaysPlasma exchangeEmpirical treatmentCaplacizumabFRET-based assayPrimary outcomePatientsNet monetary benefitCohort simulationCost-effectiveness evaluationPurpuraTesting strategies
2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategiesCost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura
Allen C, Ito S, Butt A, Purcell A, Richmond R, Cuker A, Goshua G. Cost-Effectiveness of Rapid Hemosil Versus in-House and Send-out ADAMTS13 Activity Testing in the Care of Patients with Immune Thrombotic Thrombocytopenic Purpura. Blood 2023, 142: 368. DOI: 10.1182/blood-2023-184927.Peer-Reviewed Original ResearchImmune thrombotic thrombocytopenic purpuraTherapeutic plasma exchangeIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraPLASMIC scoreIncremental net monetary benefitProbabilistic sensitivity analysesPlasma exchangeThrombocytopenic purpuraMedical intensive care unitADAMTS13 activity testingIntensive care unitCare of patientsActivity levelsHigh pretest probabilityClinical trial dataCost-effectiveness ratioCost-effectiveness evaluationDeterministic sensitivity analysesNet monetary benefitEmpiric treatmentAdverse eventsPrimary outcomeIll adultsCare unitCost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease
Waldron C, Ito S, Wang D, Allen C, Viswanathan G, Bona R, Cuker A, Goshua G. Cost-Effectiveness of Long-Term Prophylaxis with Plasma-Derived Vs. Recombinant Von Willebrand Factor in Severe Von Willebrand Disease. Blood 2023, 142: 3698. DOI: 10.1182/blood-2023-188018.Peer-Reviewed Original ResearchSevere von Willebrand diseaseLong-term prophylaxisIncremental net monetary benefitVon Willebrand diseasePlasma-derived von Willebrand factorIncremental cost-effectiveness ratioNet monetary benefitVon Willebrand factorProbabilistic sensitivity analysesDeterministic sensitivity analysesSevere haemophiliaWillebrand factorRecombinant von Willebrand factorWillebrand diseasePhase 3 clinical trialsHealth resource utilizationFactor replacement therapyFrequency of infusionsSubset of patientsCost of prophylaxisType 3 von Willebrand diseaseFactor replacement productsSimilar significant improvementsSevere phenotypeNon-significant reductionSecond-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy
Waldron C, Ito S, Wang D, Viswanathan G, Butt A, Goshua G. Second-Line Therapy Sequencing in Primary Warm Autoimmune Hemolytic Anemia: Splenectomy-Rituximab Versus Rituximab-Splenectomy. Blood 2023, 142: 2317. DOI: 10.1182/blood-2023-189957.Peer-Reviewed Original ResearchWarm autoimmune hemolytic anemiaSecond-line therapyAutoimmune hemolytic anemiaAdult patientsHemolytic anemiaSecond-line treatmentFirst-line treatmentPrevention of thrombosisDegree of anemiaLaparoscopic surgical techniquesPatient's disease statusQuality-adjusted life expectancyRate of infectionProbabilistic sensitivity analysesNet monetary benefitRituximab cyclesTherapy sequencingComplete remissionPartial remissionPerioperative mortalityPrimary outcomeTherapeutic sequencingLaparoscopic techniquePreferred treatmentRelapse riskThe Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis
Pei P, Fitzmaurice K, Le M, Panella C, Jones M, Pandya A, Horsburgh C, Freedberg K, Weinstein M, Paltiel A, Reddy K. The Value-of-Information and Value-of-Implementation from Clinical Trials of Diagnostic Tests for HIV-Associated Tuberculosis: A Modeling Analysis. MDM Policy & Practice 2023, 8: 23814683231198873. PMID: 37743931, PMCID: PMC10517616, DOI: 10.1177/23814683231198873.Peer-Reviewed Original ResearchIncremental net monetary benefitOptimal decisionsOptimal strategyNet monetary benefitDecision makers' willingnessHealth economic standpointSputum XpertClinical trialsEconomic outcomesHigh VOTMonetary benefitsNew clinical trial evidenceDiagnostic testsHIV-Associated TuberculosisEconomic standpointClinical trial evidenceVOI analysisPublic health decision makingValue of trialsDownstream health outcomesSouth AfricaEvaluation of trialsHealth decision makingWillingnessDecisions
2022
Cost-effectiveness of endovascular thrombectomy in acute stroke patients with large ischemic core
Sanmartin M, Katz J, Wang J, Malhotra A, Sangha K, Bastani M, Martinez G, Sanelli P. Cost-effectiveness of endovascular thrombectomy in acute stroke patients with large ischemic core. Journal Of NeuroInterventional Surgery 2022, 15: e166-e171. PMID: 36175016, DOI: 10.1136/jnis-2022-019460.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioNet monetary benefitProbabilistic sensitivity analysesEconomic evaluation studiesCost-effectiveness analysisCost-effectiveness ratioSensitivity analysisTwo-way sensitivity analysesLifetime healthcare costsMonetary benefitsLife yearsLifetime costsLifetime benefitsLarge ischemic coreStandard careCost-effective strategyEVTIschemic coreStroke patientsAIS patientsPatient's lifetimeAcute ischemic stroke patientsCostEndovascular thrombectomy treatmentCost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke
Zhou LW, Kraler L, de Havenon A, Lansberg MG. Cost‐Effectiveness of Cilostazol Added to Aspirin or Clopidogrel for Secondary Prevention After Noncardioembolic Stroke. Journal Of The American Heart Association 2022, 11: e024992. PMID: 35656996, PMCID: PMC9238703, DOI: 10.1161/jaha.121.024992.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth care costsHigher quality-adjusted life yearsNet monetary benefitLifetime quality-adjusted life yearsProbabilistic sensitivity analysesCare costsMonetary benefitsSensitivity analysisLife yearsCost inputsLifetime costsLower health care costsCost savingsCostBest available dataWillingnessSavingsMonte Carlo simulationsTreatment effectsCarlo simulationsAvailable dataBenefitsDecision treeReduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study
Stukas S, Goshua G, Kinkade A, Grey R, Mah G, Biggs CM, Jamal S, Thiara S, Lau TTY, Piszczek J, Partovi N, Sweet DD, Lee AYY, Wellington CL, Sekhon MS, Chen LYC. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 2022, 11: 100228. PMID: 35345649, PMCID: PMC8941850, DOI: 10.1016/j.lana.2022.100228.Peer-Reviewed Original ResearchDoses of tocilizumabCohort studyClinical outcomesIll patientsIll COVID-19 patientsCOVID-19Interleukin-6 inhibitorsSevere COVID-19Weight-based dosingCOVID-19 patientsDrug shortagesNet monetary benefitMedian CRPControl cohortTocilizumabPatientsAssumed willingnessDexamethasoneComparable reductionMortalityPhysiological responsesSignificant differencesOnly groupDoseDoses
2021
On All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery
Leeds IL, Drabo EF, Lehmann LS, Safar B, Johnston FM. On All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery. Diseases Of The Colon & Rectum 2021, 64: 744-753. PMID: 33955409, PMCID: PMC8835996, DOI: 10.1097/dcr.0000000000001926.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisProbabilistic sensitivity analysesNet monetary benefitIncremental cost-effectiveness ratioTotal costCost-effectiveness ratioMonetary benefitsSensitivity analysisBreakeven costDominant strategyEconomic costsDecision analysis methodologyCostHypothetical scenariosAlto riesgoEl análisisAnálisisEconómicoBenefitsAnalysis methodologyReducción
2020
Cost-utility of colorectal cancer screening at 40 years old for average-risk patients
Azad NS, Leeds IL, Wanjau W, Shin EJ, Padula WV. Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. Preventive Medicine 2020, 133: 106003. PMID: 32001308, PMCID: PMC8710143, DOI: 10.1016/j.ypmed.2020.106003.Peer-Reviewed Original ResearchQuality-adjusted life yearsMultivariable probabilistic sensitivity analysesNet monetary benefitIncremental cost-utility ratioLimited societal perspectiveCost-utility ratioProbabilistic sensitivity analysesMonetary benefitsSocietal perspectiveLife yearsAvailable screening modalitiesFavorable interventionWillingnessSensitivity analysisPayStandard screeningCostCT Angiography for Triage of Patients with Acute Minor Stroke: A Cost-effectiveness Analysis.
Wu X, Hughes DR, Gandhi D, Matouk CC, Sheth K, Schindler J, Wira C, Wintermark M, Sanelli P, Malhotra A. CT Angiography for Triage of Patients with Acute Minor Stroke: A Cost-effectiveness Analysis. Radiology 2020, 294: 580-588. PMID: 31934828, DOI: 10.1148/radiol.2019191238.Peer-Reviewed Original ResearchConceptsLarge vessel occlusionAcute minor strokeBest medical managementMinor strokeCT angiographyMedical managementProbabilistic sensitivity analysesLower health benefitsImmediate thrombectomyHealth benefitsHealth outcomesVascular imagingAcute ischemic strokeMarkov decision-analytic modelWorse health outcomesImproved health outcomesDecision analytic modelNet monetary benefitIntravenous thrombolysisIschemic strokeYounger patientsThrombectomy strategyPatientsAngiographyStroke
2015
Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis
Malhotra A, Wu X, Kalra VB, Schindler J, Matouk CC, Forman HP. Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis. American Journal Of Neuroradiology 2015, 37: 330-335. PMID: 26450540, PMCID: PMC7959958, DOI: 10.3174/ajnr.a4515.Peer-Reviewed Original ResearchConceptsCost-effective imaging strategyNet monetary benefitHealth care payer perspectiveIncremental cost-effectiveness ratioCare payer perspectiveCost-effectiveness analysisCost-effective strategyCost-effectiveness ratioEconomic evaluationMonetary benefitsDominant strategyMain indicatorsPayer perspectiveSelective DSAComparable utilityUtility perspectiveDecision tree analysisSelective anticoagulationSensitivity analysisCostImmense controversyHigh costCTA sensitivityParameter valuesHorizonRedefining Overuse to Include Costs: A Decision Analysis for Computed Tomography in Minor Head Injury
Melnick ER, Keegan J, Taylor RA. Redefining Overuse to Include Costs: A Decision Analysis for Computed Tomography in Minor Head Injury. The Joint Commission Journal On Quality And Patient Safety 2015, 41: 313-ap2. PMID: 26108124, DOI: 10.1016/s1553-7250(15)41041-4.Peer-Reviewed Original ResearchConceptsNet monetary benefitCurrent clinical decision rulesMonetary benefitsInclusion of costsCosts outweigh benefitsDecision analysisDecision analytic modelTwo-way sensitivity analysesDecision rulesProbability of lesionCanadian CT Head RuleMain driversOnly effectivenessCostSignificant impactSensitivity analysisCost of CT
2014
Cost-Effectiveness of Angiographic Imaging in Isolated Perimesencephalic Subarachnoid Hemorrhage
Kalra VB, Wu X, Forman HP, Malhotra A. Cost-Effectiveness of Angiographic Imaging in Isolated Perimesencephalic Subarachnoid Hemorrhage. Stroke 2014, 45: 3576-3582. PMID: 25336513, DOI: 10.1161/strokeaha.114.006679.Peer-Reviewed Original ResearchConceptsOptimal strategyNet monetary benefitCost-effectiveness analysisComprehensive cost-effectiveness analysisCost-effective strategyBase case scenarioDistributional variablesMonetary benefitsLife yearsWillingnessBase caseSensitivity analysisMonte Carlo simulationsInitial CTAPayCarlo simulationsPart of followCostStrategiesVariablesBenefitsDecision treeCase scenarioPurpose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply